Cargando…
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity betw...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123959/ https://www.ncbi.nlm.nih.gov/pubmed/34007150 http://dx.doi.org/10.2147/OPTH.S304030 |
_version_ | 1783693069336444928 |
---|---|
author | Tran, Thi Ha Chau Erginay, Ali Verdun, Stephane Fourmaux, Eric Le Rouic, Jean-François Uzzan, Joel Milazzo, Solange Baillif, Stephanie Kodjikian, Laurent |
author_facet | Tran, Thi Ha Chau Erginay, Ali Verdun, Stephane Fourmaux, Eric Le Rouic, Jean-François Uzzan, Joel Milazzo, Solange Baillif, Stephanie Kodjikian, Laurent |
author_sort | Tran, Thi Ha Chau |
collection | PubMed |
description | AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy since at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Visual acuity, OCT findings and number of IAI were assessed at 6 months and one year. RESULTS: Forty-six eyes were included. Indications for vitrectomy were epiretinal membrane (58.7%), intravitreal hemorrhage (26.1%), and vitreomacular traction (8.7%), retinal detachment (4.3%), and other cause (4.3%). Median duration of macular edema was 3 years. Median interval between vitrectomy and first visit was 9 months. Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%). Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters (p <0.001) and central subfield thickness (CST) decreased significantly (−108μm, p < 0.001) at 1 year. Mean number of injections was 9.3 and mean interval injection was 5.8 weeks. CONCLUSION: These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov, registration Number NCT02874859. |
format | Online Article Text |
id | pubmed-8123959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81239592021-05-17 One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema Tran, Thi Ha Chau Erginay, Ali Verdun, Stephane Fourmaux, Eric Le Rouic, Jean-François Uzzan, Joel Milazzo, Solange Baillif, Stephanie Kodjikian, Laurent Clin Ophthalmol Original Research AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy since at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Visual acuity, OCT findings and number of IAI were assessed at 6 months and one year. RESULTS: Forty-six eyes were included. Indications for vitrectomy were epiretinal membrane (58.7%), intravitreal hemorrhage (26.1%), and vitreomacular traction (8.7%), retinal detachment (4.3%), and other cause (4.3%). Median duration of macular edema was 3 years. Median interval between vitrectomy and first visit was 9 months. Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%). Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters (p <0.001) and central subfield thickness (CST) decreased significantly (−108μm, p < 0.001) at 1 year. Mean number of injections was 9.3 and mean interval injection was 5.8 weeks. CONCLUSION: These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov, registration Number NCT02874859. Dove 2021-05-11 /pmc/articles/PMC8123959/ /pubmed/34007150 http://dx.doi.org/10.2147/OPTH.S304030 Text en © 2021 Tran et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Tran, Thi Ha Chau Erginay, Ali Verdun, Stephane Fourmaux, Eric Le Rouic, Jean-François Uzzan, Joel Milazzo, Solange Baillif, Stephanie Kodjikian, Laurent One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema |
title | One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema |
title_full | One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema |
title_fullStr | One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema |
title_full_unstemmed | One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema |
title_short | One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema |
title_sort | one-year outcome of aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123959/ https://www.ncbi.nlm.nih.gov/pubmed/34007150 http://dx.doi.org/10.2147/OPTH.S304030 |
work_keys_str_mv | AT tranthihachau oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT erginayali oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT verdunstephane oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT fourmauxeric oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT lerouicjeanfrancois oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT uzzanjoel oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT milazzosolange oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT baillifstephanie oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema AT kodjikianlaurent oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema |